Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
出版年份 2019 全文链接
标题
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
作者
关键词
Anti-angiogenic, Tyrosine kinase inhibitors, VEGF, Immunotherapy
出版物
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-03-14
DOI
10.1186/s13045-019-0718-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Antiangiogenic therapies in non-small-cell lung cancer
- (2018) A. Alshangiti et al. Current Oncology
- Anlotinib: First Global Approval
- (2018) Yahiya Y. Syed DRUGS
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
- (2018) Federica Grillo et al. ENDOCRINE-RELATED CANCER
- Regorafenib in the treatment of metastatic colorectal cancer
- (2018) Christelle de la Fouchardière Future Oncology
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
- (2018) Jin Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
- (2018) Jun Guo et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
- (2018) Yu Chen et al. Journal of Hematology & Oncology
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- EGFR-TKIs resistance via EGFR-independent signaling pathways
- (2018) Qian Liu et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
- (2018) Sam Lubner et al. ONCOLOGIST
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Fruquintinib: First Global Approval
- (2018) Matt Shirley DRUGS
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- The regulation of cytokine signaling by retinal determination gene network pathway in cancer
- (2018) Xinhua Zheng et al. OncoTargets and Therapy
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation
- (2017) Girolamo Ranieri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2017) Kaoru Kubota et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
- (2017) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
- (2017) Rui-Hua Xu et al. Journal of Hematology & Oncology
- Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2017) Xinyang Liu et al. Journal of Hematology & Oncology
- New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
- (2017) Kevin Zarrabi et al. Journal of Hematology & Oncology
- Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
- (2017) Shan Su et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Pazopanib: a Review in Advanced Renal Cell Carcinoma
- (2017) James E. Frampton Targeted Oncology
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
- (2017) Naomi B. Haas et al. JAMA Oncology
- Targeted Therapy for Medullary Thyroid Cancer: A Review
- (2017) S. R. Priya et al. Frontiers in Oncology
- Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
- (2016) Vasileios S. Skouras et al. BIODRUGS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Jonathan A Ledermann et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
- (2016) Nasser H. Hanna et al. LUNG CANCER
- Apatinib — new third-line option for refractory gastric or GEJ cancer
- (2016) Toru Aoyama et al. Nature Reviews Clinical Oncology
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
- (2016) Robert J. Motzer et al. ONCOLOGIST
- Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat
- (2016) Takahiro Seki et al. Nature Communications
- Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. JAMA Oncology
- Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma
- (2015) K. T. Yeung et al. CLINICAL CANCER RESEARCH
- Lenvatinib: First Global Approval
- (2015) Lesley J. Scott DRUGS
- Axitinib: A Review in Advanced Renal Cell Carcinoma
- (2015) Gillian M. Keating DRUGS
- Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
- (2015) Gillian M. Keating DRUGS
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology
- (2015) Sohita Dhillon Targeted Oncology
- Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
- (2015) Sven Mahner et al. Frontiers in Oncology
- Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
- (2014) K. Kubota et al. ANNALS OF ONCOLOGY
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
- (2012) Paulo M. Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
- (2012) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- (2008) Steven I. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now